Abstract | PURPOSE: To evaluate safety, feasibility and overall survival rates for transarterial chemoembolization (TACE) alone or combined with MR-guided laser-induced- thermotherapy (LITT) in liver metastases of non-colorectal and non- breast cancer origin. METHODS AND MATERIALS: RESULTS: A total of 110 patients (mean age 59.2 years) with 371 metastases received TACE (mean 5.4 sessions/patient, n=110) with 76 (69%) receiving LITT (mean 1.6 session/patient) afterwards. TACE resulted in a mean decrease of mean maximum diameter of 52% ± 26.6 and volume change of -68.5% ± 22.9 in the 25 patients (23%) with partial response. Stable disease (n=59, 54%). Progressive disease (n=26, 23%). The RECIST outcome after LITT showed complete response (n=13, 17%), partial response (n=1, 1%), stable situation (n=41, 54%) and progressive disease (n=21, 28%). The mean time to progression ( TTP) was 8.6 months. Median survival of all patients was 21.1 months. CONCLUSION: TACE with different protocols alone and in combination with LITT is a feasible palliative treatment option resulting in a median survival of 21.1 months for unresectable liver metastases of non-colorectal and non- breast cancer origin.
|
Authors | Thomas J Vogl, Martin Kreutzträger, Tatjana Gruber-Rouh, Katrin Eichler, Nour-Eldin A Nour-Eldin, Stephan Zangos, Nagy N N Naguib |
Journal | European journal of radiology
(Eur J Radiol)
Vol. 83
Issue 10
Pg. 1804-10
(Oct 2014)
ISSN: 1872-7727 [Electronic] Ireland |
PMID | 25082479
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Contrast Media
- Gadolinium DTPA
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(administration & dosage)
- Chemoembolization, Therapeutic
(methods)
- Combined Modality Therapy
- Contrast Media
- Disease Progression
- Female
- Gadolinium DTPA
- Humans
- Hyperthermia, Induced
(methods)
- Laser Therapy
(methods)
- Liver Neoplasms
(secondary, therapy)
- Magnetic Resonance Imaging, Interventional
- Male
- Middle Aged
- Neoadjuvant Therapy
- Palliative Care
- Retrospective Studies
- Survival Rate
|